The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

Researchers say they've discovered an already approved migraine drug that can stop symptoms hours before a severe headache ...

Ixchiq is the first preventive vaccine against the chikungunya virus authorised in Europe and the US. Among the adverse ...

The CDC and FDA advise against Ixchiq chikungunya vaccine for American travellers aged 60 and above. This is due to reported ...